KIT and glioblastoma: Bevacizumab (Bev), which targets circulating VEGF-A; multi-kinase inhibitors such as cediranib, which target VEGFRs, platelet-derived growth factor receptors (PDGFRs), and c-kit; sunitinib, which targets VEGFRs and PDGFRs; and sorafenib, which targets VEGFRs, PDGFRs, Raf, and c-kit, have all been used to treat glioblastomas.